147 related articles for article (PubMed ID: 36067617)
21. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
[TBL] [Abstract][Full Text] [Related]
22. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Richardson PG; Kumar SK; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Gimsing P; Garderet L; Touzeau C; Buadi FK; Laubach JP; Cavo M; Darif M; Labotka R; Berg D; Moreau P
J Clin Oncol; 2021 Aug; 39(22):2430-2442. PubMed ID: 34111952
[TBL] [Abstract][Full Text] [Related]
23. Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program.
Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; DeMarco D; Zhang J; Mei J; Hou J
BMC Cancer; 2016 Jan; 16():46. PubMed ID: 26821931
[TBL] [Abstract][Full Text] [Related]
24. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Minarik J; Pika T; Radocha J; Jungova A; Straub J; Jelinek T; Pour L; Pavlicek P; Mistrik M; Brozova L; Krhovska P; Machalkova K; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Capkova L; Sykora M; Kessler P; Stejskal L; Heindorfer A; Ullrychova J; Skacel T; Maisnar V; Hajek R
BMC Cancer; 2021 Jan; 21(1):73. PubMed ID: 33451293
[TBL] [Abstract][Full Text] [Related]
25. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Durie BGM; Hoering A; Sexton R; Abidi MH; Epstein J; Rajkumar SV; Dispenzieri A; Kahanic SP; Thakuri MC; Reu FJ; Reynolds CM; Orlowski RZ; Barlogie B
Blood Cancer J; 2020 May; 10(5):53. PubMed ID: 32393732
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Usmani SZ; Hoering A; Ailawadhi S; Sexton R; Lipe B; Hita SF; Valent J; Rosenzweig M; Zonder JA; Dhodapkar M; Callander N; Zimmerman T; Voorhees PM; Durie B; Rajkumar SV; Richardson PG; Orlowski RZ;
Lancet Haematol; 2021 Jan; 8(1):e45-e54. PubMed ID: 33357482
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients.
Takezako N; Kosugi H; Matsumoto M; Iida S; Ishikawa T; Kondo Y; Ando K; Miki H; Matsumura I; Sunami K; Teshima T; Iwasaki H; Onishi Y; Kizaki M; Izutsu K; Maruyama D; Tobinai K; Ghori R; Farooqui M; Liao J; Marinello P; Matsuda K; Koh Y; Shimamoto T; Suzuki K
Int J Hematol; 2020 Nov; 112(5):640-649. PubMed ID: 32949374
[TBL] [Abstract][Full Text] [Related]
28. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
29. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Siegel DS; Dimopoulos MA; Ludwig H; Facon T; Goldschmidt H; Jakubowiak A; San-Miguel J; Obreja M; Blaedel J; Stewart AK
J Clin Oncol; 2018 Mar; 36(8):728-734. PubMed ID: 29341834
[TBL] [Abstract][Full Text] [Related]
30. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Larocca A; Bonello F; Gaidano G; D'Agostino M; Offidani M; Cascavilla N; Capra A; Benevolo G; Tosi P; Galli M; Marasca R; Giuliani N; Bernardini A; Antonioli E; Rota-Scalabrini D; Cellini C; Pompa A; Monaco F; Patriarca F; Caravita di Toritto T; Corradini P; Tacchetti P; Boccadoro M; Bringhen S
Blood; 2021 Jun; 137(22):3027-3036. PubMed ID: 33739404
[TBL] [Abstract][Full Text] [Related]
31. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
32. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
[TBL] [Abstract][Full Text] [Related]
33. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Béné MC; Zweegman S; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Stoppa AM; van de Donk NWCJ; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Krevvata M; Zhang K; de Boer C; Vara S; Kampfenkel T; Vanquickelberghe V; Vermeulen J; Avet-Loiseau H; Sonneveld P
Lancet Oncol; 2021 Oct; 22(10):1378-1390. PubMed ID: 34529931
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.
Puig N; Hernández MT; Rosiñol L; González E; de Arriba F; Oriol A; González-Calle V; Escalante F; de la Rubia J; Gironella M; Ríos R; García-Sánchez R; Arguiñano JM; Alegre A; Martín J; Gutiérrez NC; Calasanz MJ; Martín ML; Couto MDC; Casanova M; Arnao M; Pérez-Persona E; Garzón S; González MS; Martín-Sánchez G; Ocio EM; Coleman M; Encinas C; Vale AM; Teruel AI; Cortés-Rodríguez M; Paiva B; Cedena MT; San-Miguel JF; Lahuerta JJ; Bladé J; Niesvizky R; Mateos MV
Blood Cancer J; 2021 May; 11(5):101. PubMed ID: 34021118
[TBL] [Abstract][Full Text] [Related]
36. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Paiva B; Mateos MV; Sanchez-Abarca LI; Puig N; Vidriales MB; López-Corral L; Corchete LA; Hernandez MT; Bargay J; de Arriba F; de la Rubia J; Teruel AI; Giraldo P; Rosiñol L; Prosper F; Oriol A; Hernández J; Esteves G; Lahuerta JJ; Bladé J; Perez-Simon JA; San Miguel JF;
Blood; 2016 Mar; 127(9):1151-62. PubMed ID: 26668134
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Rajkumar SV; Jacobus S; Callander NS; Fonseca R; Vesole DH; Williams ME; Abonour R; Siegel DS; Katz M; Greipp PR;
Lancet Oncol; 2010 Jan; 11(1):29-37. PubMed ID: 19853510
[TBL] [Abstract][Full Text] [Related]
38. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
39. DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Khouri J; Faiman BM; Grabowski D; Mahfouz RZ; Khan SN; Wei W; Valent J; Dean R; Samaras C; Jha BK; Lazarus H; Campagnaro EL; Malek E; Reed J; Karam MA; Hamilton K; Fada S; Kalaycio M; Liu H; Sobecks R; Saunthararajah Y; Chew Y; Orloff M; Reu FJ
Semin Hematol; 2021 Jan; 58(1):45-55. PubMed ID: 33509443
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Rosiñol L; Oriol A; Ríos R; Blanchard MJ; Jarque I; Bargay J; Hernández MT; Cabañas V; Carrillo-Cruz E; Sureda A; Martínez-López J; Krsnik I; González ME; Casado LF; Martí JM; Encinas C; de Arriba F; Palomera L; Sampol A; González-Montes Y; Cabezudo E; Paiva B; Puig N; Cedena MT; de la Cruz J; Mateos MV; San Miguel J; Lahuerta JJ; Bladé J
Blood; 2023 Nov; 142(18):1518-1528. PubMed ID: 37506339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
